Literature DB >> 28718307

Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology.

Joao R Galante1,2, Fausto Rodriguez3, Stuart A Grossman4, Roy E Strowd5.   

Abstract

Treatment-related changes can mimic brain tumor progression both clinically and radiographically. Distinguishing these two entities represents a major challenge in neuro-oncology. No single imaging modality is capable of reliably achieving such distinction. While histopathology remains the gold standard, definitive pathological criteria are also lacking which can further complicate such cases. We report a patient with high-grade glioma who, after initially presenting with histopathologically confirmed pseudoprogression 10 months following treatment, re-presented 3 years following concurrent chemoradiation with clinical and radiographic changes that were most consistent with progressive disease but for which histopathology revealed treatment effects without active glioma. This case highlights the potential late onset of treatment-related changes and underscores the importance of histopathologic assessment even years following initial therapy.

Entities:  

Keywords:  DWI; MRI; MRS; PET; brain cancer; diagnostic challenge; high-grade glioma; neuro-oncology; post-treatment changes; pseudoprogression; radiation necrosis; radiation therapy

Year:  2017        PMID: 28718307      PMCID: PMC6009212          DOI: 10.2217/cns-2016-0040

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  29 in total

Review 1.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

2.  Hypoxia in radiation-induced blood-spinal cord barrier breakdown.

Authors:  Y Q Li; J R Ballinger; R A Nordal; Z F Su; C S Wong
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

Authors:  Alessandra Fabi; Michelangelo Russillo; Giulio Metro; Antonello Vidiri; Salvatore Di Giovanni; Francesco Cognetti
Journal:  Anticancer Res       Date:  2009-07       Impact factor: 2.480

4.  Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.

Authors:  Geoffrey A Geiger; Weili Fu; Gary D Kao
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Pathological review of late cerebral radionecrosis.

Authors:  Yoshihiko Yoshii
Journal:  Brain Tumor Pathol       Date:  2008-11-06       Impact factor: 3.298

7.  Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.

Authors:  Nicole A Shonka; Brett Theeler; Daniel Cahill; Alfred Yung; Lynette Smith; Xiudong Lei; Mark R Gilbert
Journal:  J Neurooncol       Date:  2013-03-23       Impact factor: 4.130

8.  Pseudoprogression of low-grade gliomas after radiotherapy.

Authors:  Robert P Naftel; Ian F Pollack; Giulio Zuccoli; Melvin Deutsch; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2014-09-11       Impact factor: 3.167

9.  Histopathological correlates with survival in reoperated glioblastomas.

Authors:  Graeme F Woodworth; Tomas Garzon-Muvdi; Xiaobu Ye; Jaishri O Blakeley; Jon D Weingart; Peter C Burger
Journal:  J Neurooncol       Date:  2013-05-11       Impact factor: 4.130

Review 10.  The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence.

Authors:  Kashif Parvez; Aatif Parvez; Gelareh Zadeh
Journal:  Int J Mol Sci       Date:  2014-07-03       Impact factor: 5.923

View more
  1 in total

1.  Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.

Authors:  Vivien Richter; Uwe Klose; Benjamin Bender; Katharina Rabehl; Marco Skardelly; Jens Schittenhelm; Ghazaleh Tabatabai; Johann-Martin Hempel; Ulrike Ernemann; Cornelia Brendle
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.